Anixa announces plans to launch Phase II breast cancer vaccine trial [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The prospective trial will be designed to assess the vaccine's efficacy, along with chemotherapy and Keytruda (pembrolizumab). It aims to reduce the tumour burden and avert recurrence, potentially enhancing patient survival rates. This approach enables the inclusion of a diverse patient demographic, covering various breast cancer types. Assessing the immunological response elicited by the vaccine and comparing the clinical efficacy of standard care alone versus the combination of the vaccine and standard care will be the trial's primary goals. In addition, the study will examine the breast cancer tissue to confirm the vaccine's immunological mode of action. Scheduled to begin in 2025, the trial is expected to last two to three years. The announcement of the upcoming Phase II trial follows the initiation of a Phase I trial at Cleveland Clinic, supported by a grant from the US Department of Defense. Preliminary Phase I results indicated no safety concerns, with a majority
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer VaccinePR Newswire
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer ConferencePR Newswire
- Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Cancer Vaccines Industry Research Report 2024: Market Poised for Exponential Growth with a Projected Value of $6.7 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research SymposiumPR Newswire
ANIX
Earnings
- 9/6/24 - Beat
ANIX
Sec Filings
- 9/6/24 - Form 10-Q
- 8/1/24 - Form 4
- 7/29/24 - Form 4
- ANIX's page on the SEC website